Skip to main content
This website uses cookies to ensure you get the best experience. By continuing to use this site, you agree to the use of cookies.

Please note: Your browser does not support the features used on Addgene's website. You may not be able to create an account or request plasmids through this website until you upgrade your browser. Learn more

Please note: Your browser does not fully support some of the features used on Addgene's website. If you run into any problems registering, depositing, or ordering please contact us at [email protected]. Learn more


PT3.5/CMV-EGFRvIII Citations (3)

Originally described in: De novo induction of genetically engineered brain tumors in mice using plasmid DNA.
Wiesner SM, Decker SA, Larson JD, Ericson K, Forster C, Gallardo JL, Long C, Demorest ZL, Zamora EA, Low WC, SantaCruz K, Largaespada DA, Ohlfest JR Cancer Res. 2009 Jan 15. 69(2):431-9.
PubMed Journal

Articles Citing PT3.5/CMV-EGFRvIII

Brexpiprazole, a Serotonin-Dopamine Activity Modulator, Can Sensitize Glioma Stem Cells to Osimertinib, a Third-Generation EGFR-TKI, via Survivin Reduction. Suzuki S, Yamamoto M, Sanomachi T, Togashi K, Sugai A, Seino S, Yoshioka T, Kitanaka C, Okada M. Cancers (Basel). 2019 Jul 5;11(7). pii: cancers11070947. doi: 10.3390/cancers11070947. PubMed
Point Mutations in Retargeted gD Eliminate the Sensitivity of EGFR/EGFRvIII-Targeted HSV to Key Neutralizing Antibodies. Tuzmen C, Cairns TM, Atanasiu D, Lou H, Saw WT, Hall BL, Cohen JB, Cohen GH, Glorioso JC. Mol Ther Methods Clin Dev. 2020 Jan 13;16:145-154. doi: 10.1016/j.omtm.2019.12.013. eCollection 2020 Mar 13. PubMed
JCI20679 suppresses the proliferation of glioblastoma stem cells by activating AMPK and decreasing NFATc2 expression levels. Ando S, Kojima N, Moyama C, Fujita M, Ohta K, Ii H, Nakata S. Mol Med Rep. 2022 Jul;26(1). pii: 238. doi: 10.3892/mmr.2022.12754. Epub 2022 May 27. PubMed

If you have published an article using this material, please email us at [email protected] to have your article added to this page.